Back to resultsHuman Beta-defensin 1 in Vitiligo
Primary Purpose
Vitiligo
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
skin biopsy before and after NB-UVB phototherapy
Sponsored by
About this trial
This is an interventional diagnostic trial for Vitiligo
Eligibility Criteria
Inclusion Criteria:
- Patients with non-segmental vitiligo.
- Both genders.
- Age more than 18 years old.
- New cases or cases not receiving any treatment for at least 3 months prior to the study.
Exclusion Criteria:
- Universal or segmental vitiligo.
- Any contraindication to phototherapy treatment.
- History of autoimmune diseases or other systemic diseases.
- Any other skin disease.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
vitiligo patients
Healthy controls
Arm Description
Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy
Tissue levels of human beta-defensin 1 in healthy controls
Outcomes
Primary Outcome Measures
Tissue levels of human beta-defensin 1 before and after NB-UVB phototherapy
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03832751
Brief Title
Human Beta-defensin 1 in Vitiligo
Official Title
Estimation of Tissue Level of Human Beta-defensin 1 (HBD-1) in Vitiligo Before and After Narrowband UVB Phototherapy: a Case-control Study
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Unknown status
Study Start Date
March 2019 (Anticipated)
Primary Completion Date
December 2019 (Anticipated)
Study Completion Date
December 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
There is a need to know the role of human beta defensin-1 in vitiligo pathogenesis and the probability of finding newer and effective therapy for vitiligo in the future.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitiligo
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
25 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
vitiligo patients
Arm Type
Experimental
Arm Description
Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy
Arm Title
Healthy controls
Arm Type
Active Comparator
Arm Description
Tissue levels of human beta-defensin 1 in healthy controls
Intervention Type
Other
Intervention Name(s)
skin biopsy before and after NB-UVB phototherapy
Intervention Description
skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
Primary Outcome Measure Information:
Title
Tissue levels of human beta-defensin 1 before and after NB-UVB phototherapy
Time Frame
6 months to 1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients with non-segmental vitiligo.
Both genders.
Age more than 18 years old.
New cases or cases not receiving any treatment for at least 3 months prior to the study.
Exclusion Criteria:
Universal or segmental vitiligo.
Any contraindication to phototherapy treatment.
History of autoimmune diseases or other systemic diseases.
Any other skin disease.
12. IPD Sharing Statement
Learn more about this trial
Human Beta-defensin 1 in Vitiligo
We'll reach out to this number within 24 hrs